| Sygnis Bioscience GmbH & Co. KG Patent applications |
| Patent application number | Title | Published |
|---|
| 20120070403 | USE OF G-CSF FOR THE EXTENSION OF THE THERAPEUTIC TIME-WINDOW OF THROMBOLYTIC STROKE THERAPY - The present invention relates to the use of G-CSF and derivatives thereof for extending the therapeutic window of subsequent thrombolytic treatment of acute stroke, and thereby, allowing the diagnostic examinations which are necessary prior to the thrombolytic treatment in order to avoid hemorrhagic and other severe adverse side effects of the thrombolysis. | 03-22-2012 |
| 20100284926 | USE OF G-CSF FOR THE TREATMENT OF STROKE - The invention relates to the use of G-CSF for the treatment of cerebral stroke, particularly cerebral stroke with a large baseline infarct volume. Administration of G-CSF at a total dose of 30 to 180 μg per kg body weight over a treatment period of about 3 days is suitable for the treatment of stroke. Treatment in accordance with the invention with a total dose of 80 to 150 μg per kg body weight is preferred. | 11-11-2010 |
| 20090305289 | SCREENING METHOD TO IDENTIFY PROTECTIVE SUBSTANCES FOR THE TREATMENT OF NEURODEGENERATIVE AND/OR ISCHAEMIC DISEASES - The present invention relates to a screening method for the identification of protective substances which influence haemoglobin formation in neuronal, myocardial and/or skeletomuscular cells, as well as to recombinant constructs, host cells and transgenic animals for the implementation of this method. In addition, the present invention relates to a diagnostic method for the differential diagnosis of neurodegenerative and/or ischaemic diseases in mammals and the use of haemoglobin, a globin or a mutein or fusion protein thereof or a corresponding nucleic acid for the treatment of neurodegenerative and/or ischaemic diseases in mammals. The invention furthermore relates to constructs for gene therapy of such diseases. | 12-10-2009 |
